Complain about a product or service

Consumers Sue AstraZeneca Over Nexium Ad Campaign

October 19, 2004

• FDA Approves Nexium for Children • FDA Finds No Increased Heart Risk From Prilosec, Nexium • Do Seniors Suffer More Heartburn? • Prilosec as Effective as Expensive Prescriptions, Study Finds • Consumers Sue AstraZeneca Over Nexium Ad Campaign

Consumers of the heartburn medication Nexium are suing the drug's distributor, AstraZeneca, alleging the pharmaceutical company sought to preserve market share and profits as the patent on their blockbuster drug, Prilosec, was set to expire, by initiating a massive and misleading advertising and promotional campaign to deceive consumers into purchasing Nexium, a nearly identical new drug.

Filed in U.S. Superior Court in Los Angeles, the suit contends that the core of AstraZeneca's scheme was to use misleading information to convince consumers that Nexium was a significantly better drug than Prilosec.

The pharmaceutical planned to redirect consumer loyalty from the flagship drug Prilosec to Nexium before the expiration of Prilosec's U.S. patent and the onslaught of competition from generic manufacturers that would deprive AstraZeneca of significant profits, the suit charges.

"AstraZeneca knew that with the expiration of their Prilosec patent, they would lose market share and profits. We intend to show that they initiated a plan to deceive consumers and recoup those lost revenues," said Steve Berman, lead attorney for the plaintiffs. "This suit is a response to their deception and is a message to AstraZeneca and all pharmaceutical companies that they will be accountable to consumers for their actions."

The suit is brought by the AFL-CIO, the Congress of California Seniors, and the California Alliance for Retired Americans and seeks to be classified as a class action on behalf of consumers nationwide who purchased Nexium. All three of the organizations are members of the Prescription Access Litigation Project (PAL), a national coalition of 100 consumer organizations dedicated to fighting illegal pharmaceutical price inflation through class-action litigation.

"More and more workers cannot get the healthcare they need, and out-of-control drug prices are a huge factor," said Gerry Shea, AFL-CIO's director of governmental affairs. "The AFL-CIO is joining the Prescription Access Litigation Project and the suit against AstraZeneca because it's high time that drug companies were held accountable for deceiving American consumers into buying 'new' drugs they don't need at prices they can't afford."

Drug Ads • New Trend In Drug Ads Gets Around FDA Rule • Consumers Union Weighs In On Drug Ads • FDA Panel Wants Closer Scrutiny of Drug Ads • AMA Calls For Tighter Drug Ad Oversight • Prescription Drug Ads Influence Patients, Poll Finds • AIDS Foundation Sues Pfizer Over Viagra Ads • AMA Wants Moratorium on Consumer Ads for New Prescription Drugs • Med School Profs Cauterize Drug Ads • Consumer Group Challenges AMA on Drug Ads • AMA Takes No Position On Direct-To-Consumer Drug Ads • Consumer Drug Ads May Influence Doctors' Rx Decisions • FDA Objects to Zyrtec Ads • FDA Panel Gives Vioxx a Yellow Light • Devilish Viagra Ads Pulled • Consumers Sue AstraZeneca Over Nexium Ad Campaign

Prilosec (also known as Losec) is a proton-pump inhibitor (PPI) used to treat heartburn and was AstraZeneca's most profitable drug. By 2000, Prilosec was the most prescribed drug in the world, with global sales reaching $6 billion. But with Prilosec's patent set to expire in 2001, its loss of brand name protection and assured competition from generic drug manufacturers posed a financial vulnerability to the pharmaceutical company.

According to the suit, AstraZeneca responded to this financial threat by launching a massive advertising campaign to overshadow the perceived effectiveness of Prilosec, and persuade consumers that Nexium was a new and improved PPI.

"AstraZeneca pulled a massive 'bait and switch' on the American public," said Nan Brasmer, President of the California Alliance for Retired Americans. "Rather than looking for new drugs that would be real improvements for patients, they poured millions of dollars into promoting a drug that was far more expensive but no better than equally effective generic drugs."

The ads claimed that Nexium was proven more effective at acid inhibition than comparable drugs, the suit states. However, the clinical trials alluded to in these ads only compared Nexium at dosage levels twice those of Prilosec (40 mg to 20 mg respectively). No tests were done to compare 40 mg of Nexium to 40 mg of Prilosec.

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

Back to the top |

Home | Complaint Form | News | Recalls | FAQ |
Consumer Resources | Small Claims Guide | Lemon Law | Newsletter | Contact Us
Advertise With Us | Testimonials | Newsroom | RSS Feeds |

Terms of Use Your use of this site constitutes acceptance of the Terms of Use

Advertisements on this site are placed and controlled by outside advertising networks. ConsumerAffairs.com does not evaluate or endorse the products and services advertised. See the FAQ for more information.

Company Response Welcome If complaints about your company appear on our site, we welcome your response. Please see the Response Form for more information.

For more information, see the FAQ and privacy policy. The information on this Web site is general in nature and is not intended as a substitute for competent legal advice.  ConsumerAffairs.com Inc. makes no representation as to the accuracy of the information herein provided and assumes no liability for any damages or loss arising from the use thereof. 

Copyright © 2003-2008 ConsumerAffairs.com Inc.  All Rights Reserved.    The contents of this site may not be republished, reprinted, rewritten or recirculated without written permission.